Change in brain and lesion volumes after CEE therapies: The WHIMS-MRI studies

Neurology

Volumn 82, Issue 5, 2014, Pages 427-434

  Coker, Laura H ^a   Espeland, Mark A ^a   Hogan, Patricia E ^a   Resnick, Susan M ^d   Bryan, R Nick ^e   Robinson, Jennifer G ^f   Goveas, Joseph S ^g   Davatzikos, Christos ^e   Kuller, Lewis H ^h   Williamson, Jeff D ^b   Bushnell, Cheryl D ^c   Shumaker, Sally A ^a  

^a Division of Public Health Sciences   (United States)

^b Department of Internal Medicine and Geriatrics ^*  (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO;

AGED; ARTICLE; BASAL GANGLION; BRAIN ATROPHY; BRAIN DAMAGE; BRAIN ISCHEMIA; BRAIN SIZE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; FRONTAL LOBE; GRAY MATTER; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VERY ELDERLY; WHITE MATTER LESION;

AGED; BRAIN; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; ORGAN SIZE; WOMEN'S HEALTH;

EID: 84895726348     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000079     Document Type: Article

References (29)

1. Wnuk A, Korol DL, Erickson KI. Estrogens, hormone therapy, and hippocampal volume in postmenopausal women. Maturitas 2012;73:186-190.
2. Resnick SR, Espeland MA, Jaramillo SA, et al. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology 2009;72:135-142.
3. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 2003;13:S5-S17.
4. Jaramillo SA, Felton D, Andrews LA, et al. Enrollment in a brain magnetic resonance study: results from the Women's Health Initiative Memory Study Magnetic Resonance Imaging Study (WHIMS-MRI). Acad Radiol 2007;14:603-612.
5. Coker LH, Hogan PE, Bryan NR, et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. Neurology 2009;72:125-134.
6. Lao Z, Shen D, Liu D, et al. Computer-assisted segmentation of white matter lesions in 3D MR images using support vector machine. Acad Radiol 2008;15:300-313.
7. Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure in people with type 2 diabetes (ACCORD MIND): a randomized open-label study. Lancet Neurol 2011;10:969-977.
8. Driscoll I, Davatzikos C, An Y, et al. Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology 2009;72:1906-1913.
9. Anbeek P, Vincken KL, van Osch MJ, Bisschops RH, van der Ground J. Automatic segmentation of different-sized white matter lesions by voxel probability estimation. Med Image Anal 2004;8:205-215.
10. Shen D, Davatzikos C. HAMMER: hierarchical attribute matching mechanism for elastic registration. IEEE Trans Med Imaging 2002;21:1421-1439.
11. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
12. Lord C, Buss C, Lupien SJ, Pruessner JC. Hippocampal volumes are larger in postmenopausal women using estrogen therapy compared to past users, never users, and men: a possible window of opportunity effect. Neurobiol Aging 2008;29:95-101.
13. Lord C, Engert V, Lupien SJ, Pruessner JC. Effect of sex and estrogen therapy on the aging brain: a voxel-based morphometry study. Menopause 2010;17:846-851.
14. Brinton RD. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci 2008;31:529-537.
15. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from theWomen's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
16. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA 2003;289:2673-2684.
17. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-1712.
18. Espeland MA, Brunner RL, Hogan PA, et al. Long term effects of conjugated equine estrogen therapies on domainspecific cognitive function: results from the Women's Health Initiative Study of Cognitive Aging (WHISCA) Extension. J Am Geriatr Soc 2010;58:1263-1271.
19. Espeland MA, Tindle HA, Bushnell CA, et al; Women's Health Initiative Memory Study. Brain volumes, cognitive impairment, and conjugated equine estrogens. J Gerontol A Biol Sci Med Sci 2009;64:1243-1250.
20. Casanova R, Espeland MA, Goveas J, et al. Application of machine learning methods to describe the effects of conjugated equine estrogens therapy on region-specific brain volumes. Magn Reson Imaging 2011;29:546-553.
21. Tooze JA, Gaussoin SA, Resnick SM, et al; Women's Health Initiative Memory Study. A uniform approach to modeling risk factor relationships for ischemic lesion prevalence and extent: the Women's Health Initiative Magnetic Resonance Imaging Study. Neuroepidemiology 2010;34:55-62.
22. Haan M, Espeland MA, Klein BE, et al. Cognitive function and retinal and ischemic brain changes: the Women's Health Initiative. Neurology 2012;78:942-949.
23. Yao J, Rettberg JR, Klosinski LP, Cardenas E, Brinton RD. Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol Aspects Med 2011;32: 247-257.
24. Yao J, Brinton RD. Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. Adv Pharmacol 2012;64:327-371.
25. Espeland MA, Shumaker SA, Leng I, et al. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 2013;173:1429-1436.
26. Zhang QG, Han D, Wang RM, et al. C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection. Proc Natl Acad Sci USA 2011;108:E617-E624.
27. Zhao L, Yao J, Mao Z, Chen S, Wang Y, Brinton RD. 17b-Estradiol regulates insulin-degrading enzyme expression via an ERb/P13-K pathway in hippocampus: relevance to Alzheimer's prevention. Neurobiol Aging 2011; 32:1949-1963.
28. DeGroot JC, De Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM. Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 2000;57:1071-1076.
29. Havlik RJ, Foley DJ, Sayer B, Masaki K, White L, Launer LJ. Variability in midlife systolic blood pressure is related to late-life brain white matter lesions: the Honolulu-Asia Aging Study. Stroke 2002;33:26-30.